NEW YORK (GenomeWeb) – Metabolon announced today that it has signed a deal to commercialize its Quantose IR insulin resistance test in 30 international markets with European clinical laboratory network Synlab.

Quantose IR is a blood-based test uses insulin and three non-glycemic biomarkers to assess the risk of a patient developing prediabetes. Under the terms of the arrangement, Synlab will introduce the test first in Spain and then in other markets throughout Europe, Latin America, and the Middle East during 2016.

Additional terms of the deal were not disclosed.